About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, FDA approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Clinical trials demonstrate weight reductions exceeding those seen with semaglutide in head-to-head comparisons. Compounded formulations are offered by telehealth and functional medicine providers across the US. It represents the current clinical benchmark for pharmacological weight management. Mechanism of action: Tirzepatide activates two incretin receptors simultaneously — the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GLP-1 activation suppresses appetite, slows gastric emptying, and potentiates insulin secretion; GIP activation independently stimulates insulin release and may reduce some of the GI side effects associated with pure GLP-1 agonism. The dual mechanism produces greater appetite suppression and metabolic improvement than either receptor pathway alone, which accounts for the superior weight reduction seen in clinical trials relative to semaglutide. Clinical evidence: The SURMOUNT trial program established tirzepatide's weight reduction profile. SURMOUNT-1 (2022) found a mean weight reduction of 22.5% over 72 weeks at the highest dose (15mg/week) vs 2.4% with placebo — the largest mean weight reduction reported for any approved pharmacological intervention at that time. SURMOUNT-5 (2024) was a direct head-to-head comparison with semaglutide 2.4mg: tirzepatide 10mg and 15mg produced significantly greater weight reductions (20.2% vs 13.7% for semaglutide). The SURPASS trials established cardiometabolic and glycaemic benefits in T2D contexts. Tirzepatide vs semaglutide: Tirzepatide's dual GIP+GLP-1 mechanism produces greater mean weight reductions in trials but also a distinct side effect profile. GI tolerability may be slightly better than pure GLP-1 agonism for some users due to the GIP component, though nausea and gastrointestinal symptoms remain the most common adverse effects. Semaglutide has a larger body of long-term safety data; tirzepatide has superior head-to-head efficacy data. Prescribers select between them based on clinical context, cost, access, and patient response history. Access and regulatory status: Tirzepatide requires a prescription from a licensed provider. Branded formulations (Mounjaro, Zepbound) are available at licensed pharmacies. Compounded tirzepatide has been subject to evolving FDA guidance around shortage status; access through compounding channels varies by jurisdiction and regulatory period. Providers offering tirzepatide-based programs are indexed in the PeptideBase directory.
Tirzepatide Benefits & Research Areas
Research Signals
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- May 13, 2022
- Source
- View FDA source →
FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
8 sources cited · 3 strong · 5 moderate
3 RCTs · 2 Cohorts · 3 Reviews
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Lancet · 2023
Research found that tirzepatide 15 mg reduced mean body weight by 14.7% over 72 weeks compared with 3.2% for placebo in adults with obesity and type 2 diabetes, with more than 79% of participants achieving at least 5% weight reduction.
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine · 2022
In the 72-week phase 3 SURMOUNT-1 trial, tirzepatide 15 mg reduced mean body weight by 20.9% compared with 3.1% for placebo in adults with obesity, with 57% of participants achieving at least 20% weight reduction.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
New England Journal of Medicine · 2021
In this 40-week phase 3 trial, tirzepatide at all three doses produced significantly greater reductions in HbA1c and body weight compared with semaglutide 1 mg in adults with type 2 diabetes, with the highest dose achieving approximately 5.5 kg additional weight reduction over semaglutide.
Show 5 more sources ↓
Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.
Dermatol Surg · 2026
# Summary Research found that while glucagon-like peptide-1 receptor agonists—including tirzepatide—have not yet been proven to directly affect lipedema progression, translational evidence suggests these therapies may influence inflammatory and fibrotic pathways relevant to the condition and could potentially serve as adjunctive treatment options. This study demonstrated that very limited direct patient evidence currently exists, with only a small case series showing improvements in pain and limb volume, indicating that further research is needed to establish the clinical role of these therapies in lipedema management.
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study.
Diabetes Ther · 2026
# Summary Research found that tirzepatide demonstrated significant effectiveness in real-world clinical practice among Japanese patients with type 2 diabetes, producing meaningful reductions in both blood sugar control (HbA1c) and body weight over a 24-week period. This study demonstrated that patients who had not previously received GLP-1 receptor agonist therapy showed greater improvements in blood sugar levels, and that baseline blood sugar levels—rather than body mass index—were the primary predictor of treatment response.
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
Dermatol Surg · 2026
# Summary Research found that glucagon-like peptide-1 receptor agonists (GLP-1RAs), including tirzepatide, are associated with hair loss conditions such as telogen effluvium and androgenic alopecia, with risk potentially increasing with longer treatment duration, greater weight loss, and higher doses. This study demonstrated that while proposed mechanisms include weight loss-related changes and hormonal influences, the evidence remains conflicting, and dermatology practitioners should monitor patients receiving GLP-1RA therapy for these potential adverse effects.
Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.
J Lipid Atheroscler · 2026
# Summary Research found that tirzepatide, a dual GIP/GLP-1 receptor agonist, produced significant reductions in blood sugar levels (hemoglobin A1c) and body weight in patients with type 2 diabetes, while also improving lipid parameters and lowering blood pressure. This study demonstrated that these cardiovascular and metabolic benefits occurred without increasing serious hypoglycemia risk, with adverse events primarily consisting of mild gastrointestinal symptoms comparable to other GLP-1 receptor agonists.
DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
Mol Ther Nucleic Acids · 2026
# Summary Research found that using MYO Technology—a DNA-based delivery platform administered via intramuscular injection—enabled incretin receptor agonists to produce sustained weight loss and glucose control in obesity models with effects lasting over one year from a single administration. This study demonstrated that engineering these agonists to cross the blood-brain barrier further enhanced treatment efficacy, potentially reducing the frequent dosing burden associated with currently available incretin receptor agonist medications.
Tirzepatide Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Common monitoring markers in research protocols
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Research Stacks
Browse all →Where to Buy Tirzepatide — Providers & Availability
486 providersCoverage expanding
No verified providers currently list Tirzepatide. Get notified when one does, or explore providers carrying similar peptides in the Fat Loss category.
Stay updated on verified Tirzepatide providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Tirzepatide
Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, FDA approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Clinical trials demonstrate weight reductions exceeding those seen with semaglutide in head-to-head comparisons.
Fat Loss.
Research on Tirzepatide primarily documents effects related to Fat Loss. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Tirzepatide include active cancer history. This is educational information only — consult a qualified healthcare professional before use.
486 providers in the directory currently offer Tirzepatide.
Research found that tirzepatide 15 mg reduced mean body weight by 14.7% over 72 weeks compared with 3.2% for placebo in adults with obesity and type 2 diabetes, with more than 79% of participants achieving at least 5% weight reduction.
Tirzepatide is featured in the following research stacks on PeptideBase: AOD-9604 + Tirzepatide: Advanced Body Composition.